ECG Diagnostics Software Platform Accurdia and Cardiac Medical Technology Company Heartbeam joins forces Accorkardia ECG analysis software available on Heartbeam devices.
Heartbeam’s cable-free 12-lead ECG system captures electrical signals from the heart from three directions to assess arrhythmia.
The platform is designed for portable devices, allowing doctors to identify heart health trends and acute conditions wherever the patient is.
In January, Heartbeam submitted to the FDA a 510(k) application of 12-lead ECG synthesis software to assess rhythm and arrhythmias, sinuses, atrial fibrillation, atrial hypertrophy, bradycardia, tachycardia and sinuses.
AccureCG aims to simplify the interpretation of ECGs by identifying visibility and hidden signals, and converting them into diagnostics and broad biomarkers.
Companies argue that by adding an automated ECG interpretation platform to Heartbeam devices that is independent of corcurkardia’s device, it could potentially manage heart health faster and more accurately.
“This collaboration is a major step forward in providing a more accessible and scalable solution for remote cardiac monitoring,” Heartbeam CEO Robert Eno said in a statement.
“Arcurkardia shares our mission to improve cardiac outcomes through innovation, and together we can accelerate the delivery of unprecedented cardiac insights to individuals and physicians outside of our healthcare facilities.”
Bigger trends
In February, Heartbeam announced a public offering of 5.8 million common stock at $1.70 per share. The company was expecting a total revenue of $10 million from its offering.
In a statement, the company said it uses net revenues for commercial preparatory activities, research and development, clinical and regulatory projects and working capital.
Accurkardia received it in January Designation of FDA breakthrough devices with ECG-based AI-equipped AK+ Guard hyperkalemia detection software.
Investigative techniques use lead I ECG data to alert patients and clinicians of episodes of moderate to severe hyperkalemia (excess potassium in the blood), leading to sudden cardiac arrest.
In 2024, Accardia’s Aortic Stenosis (AVS) ECG-based AI screening software was granted the FDA Breakthrough Device Designation.
